Strut Thickness

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 1731 Experts worldwide ranked by ideXlab platform

Ron Waksman - One of the best experts on this subject based on the ideXlab platform.

  • Meta-Analysis of the Impact of Strut Thickness on Outcomes in Patients With Drug-Eluting Stents in a Coronary Artery.
    The American journal of cardiology, 2018
    Co-Authors: Micaela Iantorno, Michael J. Lipinski, Hector M. Garcia-garcia, Brian J. Forrestal, Toby Rogers, Deepakraj Gajanana, Kyle Buchanan, Rebecca Torguson, William S. Weintraub, Ron Waksman
    Abstract:

    The aim of this network meta-analysis is to assess the impact of Strut Thickness on clinical outcomes in patients who underwent percutaneous coronary intervention. We searched Medline/PubMed and performed a Bayesian network meta-analysis to compare outcomes of patients who underwent percutaneous coronary intervention with drug-eluting stents (DES) of different Strut Thicknesses (ultrathin 60 to 80 μm; thin 81 to 100 μm; intermediate 101 to 120 μm; thick ≥120 μm). Studies comparing DES with similar Strut Thickness, bare metal stents, and fully bioresorbable scaffolds were excluded. Odds ratios with credible intervals (OR [CrIs]) were generated with random-effects models to compare outcomes. Our primary end point was stent thrombosis (ST). We identified 69 RCTs including 80,885 patients (ultrathin group = 10,219; thin group = 36,575; intermediate group = 11,399; thick group = 22,692). Mean age was 64 ± 11 years and 75% were male gender. When compared with thick-Strut DES, ultrathin Struts had significant less ST and myocardial infarction (OR 0.43 [CrI 0.27 to 0.68]; and OR 0.73 [CrI 0.62 to 0.92], respectively). Sensitivity analysis including only studies with permanent polymer DES gave similar results. Improvement in DES technology with thinner Struts is associated with significant reduction in ST and myocardial infarction compared with thicker Struts.

  • CRT-600.01 A Network Meta-analysis Comparing Clinical Outcomes of Thick- and Thin-Strut Biodegradable Polymer Stents with Second-Generation Drug-Eluting Stents
    JACC: Cardiovascular Interventions, 2018
    Co-Authors: Brian J. Forrestal, Michael J. Lipinski, Micaela Iantorno, Rebecca Torguson, Ron Waksman
    Abstract:

    We performed a network meta-analysis of randomized controlled trials (RCTs) to assess the impact of biodegradable polymer stent Strut Thickness on clinical outcomes in patients undergoing percutaneous coronary intervention (PCI). We searched MEDLINE/PubMed and performed a Bayesian network meta-

  • CRT-100.87 Thinner Struts in Drug-eluting Stents Are Associated With Better Outcomes: A Network Meta-analysis of Randomized Controlled Trials
    JACC: Cardiovascular Interventions, 2018
    Co-Authors: Micaela Iantorno, Michael J. Lipinski, Hector M. Garcia-garcia, Brian J. Forrestal, Deepakraj Gajanana, Kyle Buchanan, Rebecca Torguson, Ron Waksman
    Abstract:

    We performed a network meta-analysis of randomized controlled trials (RCTs) to assess the impact of Strut Thickness on clinical outcomes in patients undergoing percutaneous coronary intervention (PCI). We searched Medline/PubMed and performed a Bayesian network meta-analysis to compare outcomes of

  • Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent.
    EuroIntervention, 2009
    Co-Authors: Ron Waksman, Rajbabu Pakala
    Abstract:

    Advances in coronary stent technology, including refinement of the stent alloy, Strut Thickness, stent geometry, passive coating, and drug elution, have dramatically enhanced the safety and efficacy of percutaneous coronary intervention (PCI) with stenting. Stents are currently used in over 90% of coronary interventions and the use of drug-eluting stents (DES) has been disseminated to more complex lesion subsets such as total occlusions, long lesions, bifurcation lesions, and for patients with acute myocardial infarction. DES continue to demonstrate reduction in restenosis and the need for repeat revascularisation but are associated with delayed healing and re-endothelialisation, which have led to an increased rates of late stent thrombosis, dependency on prolonged dual antiplatelet therapy, impaired in-vessel reactivity, and chronic inflammation. As scientists and clinicians better understand the mechanism for late restenosis and stent thrombosis, a variety of solutions in regard to stent technology have been proposed, including stent coating, polymer bioabsorption, and fully biodegradable stents. Bare metal stents were improved by the reduction of Strut Thickness, changes in stent geometry, and the addition of passive coating, which lead to improvements in efficacy and reduction of restenosis. In addition, there is continued improvement in the polymer technology for DES, including new biocompatible, thinner durable polymers, and bioabsorbable polymers that completely bioabsorb within 3-12 months after stent implantation. These features potentially minimise the chronic inflammatory response and late stent thrombosis. Finally, fully bioabsorbable stents, both polymeric and metallic, continue to be developed in order to eliminate any late stenting effects and potentially may enable complete vessel restoration. This manuscript will discuss the wide variety of new stent technologies and compare and contrast durable metallic and polymeric stents to current biodegradable stent technology.

Zhiyuan Song - One of the best experts on this subject based on the ideXlab platform.

Pawel Gasior - One of the best experts on this subject based on the ideXlab platform.

Xin Zhou - One of the best experts on this subject based on the ideXlab platform.

Jenn Mcgregor - One of the best experts on this subject based on the ideXlab platform.

Related terms

Strut Thickness - 15 days free trial to Access Experts & Abstracts